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Intratumoral plasmacytoid dendritic cells associate with
increased survival in patients with follicular lymphoma
Abstract
Gene array studies on follicular lymphoma (FL) have associated non-malignant tumor-infiltrating
immune cells with patient survival. We examined the role of such cells detectable by
immunohistochemistry in a tissue microarray, focusing on plasmacytoid dendritic cells (pDCs). These
cells physiologically produce interferon-α, which has been used in the therapy of FL. High numbers of
pDCs are associated with increased survival, and so are high numbers of CD3+ T cells. The regular
distribution of pDCs within T cell areas is reflected by a weak but significant correlation between pDCs
and T cells. However, in multivariate Cox models, CD123 proved to be an independent prognostic
factor. These findings support the hypothesis of an association of pDCs with better prognosis by
producing interferon. Furthermore, due to a linear relationship between pDCs and survival shown by
means of Kaplan-Meier plots, immunohistochemical staining of CD123 could serve as a prognostic tool
for patients with FL.
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Abstract
Gene array studies on follicular lymphoma (FL) have associated nonmalignant tumor-
infiltrating immune cells with patients’ survival. We examined the role of such cells 
detectable by immunohistochemistry in a tissue microarray, focusing on plasmacytoid 
dendritic cells (pDC). These cells physiologically produce interferon alpha, which has 
been used in the therapy of FL.
High numbers of pDC are associated with increased survival, and so are high 
numbers of CD3+ T cells. The regular distribution of pDC within T cell areas is 
reflected by a weak but significant correlation between pDC and T cells. However, in 
multivariate Cox models, CD123 proved to be an independent prognostic factor.
These findings support the hypothesis of an association of pDC with better prognosis 
by producing interferon. Furthermore, due to a linear relationship between pDC and 
survival shown by means of Kaplan-Meier plots, immunohistochemical staining of 
CD123 could serve as a prognostic tool for patients with FL.
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Introduction
Follicular lymphoma (FL) is the second most frequent type of malignant lymphoma 
(NHL), accounting for up to 20% of lymphoma patients. Only diffuse large B-cell 
lymphoma (DLBCL) is more common.1
The course of disease is highly variable with a median survival time of 8 to 10 years.2
Patients can show slow progression over a period of 20 years, while on the other 
hand tumors can be aggressive resulting in death within less than one year.3
Identification of these patients is still challenging and has impact on therapeutic 
modalities. Long-time remission is possible in early Ann Arbor stages I or II, which 
account for at most 15% of patients. For patients with advanced lymphoma stages III 
and IV, therapy is usually not initiated until the disease becomes symptomatic.2 After 
this period of watchful waiting, there is often good initial response to various kinds of 
therapies.4 As patients relapse over time, durations of remission get shorter and 
finally patients die either of progressive disease or after transformation into DLBCL. 
This occurs in about 30% of tumors after accumulation of numerous genetic 
alterations.5 However, it appears questionable whether such random events in the 
genome of tumor cells are responsible for the clinical heterogeneity of the disease.6
The follicular lymphoma international prognostic index (FLIPI) represents a effective 
clinical scoring system to estimate prognosis in FL. It includes patients’ age (older 
than 60 years versus 60 years and younger), Ann Arbor stage (III/IV versus I/II), 
number of lymph node sites affected (more than 4 versus up to 4), hemoglobin level 
(less versus at least 120 g/L) and serum LDH level (above normal versus normal).7,8
However, it does not include intrinsic tumor properties. For a long time, the only 
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prognostic features within the tumor itself were histological grading according to 
WHO criteria or determination of the proliferation index.9,10 Increasing evidence 
points to a role of tumor stroma, especially intratumoral reactive cells in 
determinating the course of disease and in modulating tumor progression by 
changing microenvironmental properties and by interacting with tumor cells.6,11-20
Intratumoral leucocytes were described already 150 years ago by Rudolf Virchow, 
who suggested a connection between chronic inflammation and cancerogenesis. 
Esophageal adenocarcinoma and pleural mesothelioma are well-known examples of 
inflammation induced malignancies. T cells, macrophages and dendritic cells are 
found in various malignant diseases. They have been associated with prognosis, 
sometimes favourable, sometimes poor.21 Gene expression studies identified T cells, 
macrophages and dendritic cells to impact on prognosis in FL.6,13,14 In this study, we 
intended to emulate these results on tissue sections. We focused on CD123+ pDC, 
as they are known to have various immunoregulatory functions.22 Macrophages, T 
cell subsets and vessel density have been adressed by others.14-19,23 Of note, pDC 
produce important amounts of type-I-interferon during maturation, especially 
interferon-alpha (IFN-α)24-26, and IFN-α was used with success in the therapy of FL 
prior to the advent of CD20 targeting therapy regimen.27
Page 5/28
Patients, materials and methods
PATIENT CHARACTERISTICS
Patients were retrieved by searching the pathology information system of the 
Department of Pathology at University Hospital Zurich, Switzerland. Between 
January 1990 and August 2005, 288 patients with FL were examined with a total of 
373 biopsies, and all these cases were considered for the study. Paraffin sections 
were reviewed systematically by M. K. including staining for bcl-2, bcl-6, CD10, CD20 
and CyclinD1 and graded according to WHO criteria. All samples other than genuine 
FL were excluded: Follicular hyperplasia (10 patients), composite-lymphoma (one 
patient), mantle cell lymphoma (two patients), cutaneous FL (one patient) and FL 
after transformation in diffuse large B-cell lymphoma (DLBCL, 18 patients). 34 
patients lacked sufficient clinical or survival information and were therefore excluded 
from the study. For further analysis, only initial biopsy specimens before therapy 
were included. 47 patients fell away because the available biopsy specimen had 
been obtained after initiation of therapy, 36 because their biopsies had been obtained 
after a period of watchful waiting without therapy while the initial biopsy specimen 
was not available either. This resulted in a total of 139 patients. 
Survival data were obtained from the Cancer Registry of the Canton of Zurich. 
Clinical data were obtained by review of the original patient charts. Treatment was 
non uniform and complete information on the therapy regimen was not available in 
every patient. Therefore, only limited survival analysis according to individual 
treatment groups was possible. Subdivision resulted in unreasonably small groups to 
compare. The study was approved by the ethics commission of the Canton of Zurich.
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TISSUE MICROARRAY CONSTRUCTION AND IMMUNOHISTOCHEMISTRY
A tissue microarray (TMA) was constructed by taking duplicate cores of 650 microns 
from each biopsy28,29. The quality of the sampled area and the presence of neoplastic 
follicles were ascertained first by hematoxylin and eosin (HE) stained sections. Slides 
were cut at 2.5 microns. Immunohistochemistry was performed on a Ventana 
Benchmark XT automated stainer (Ventana Medical Systems S.A., Illkirch, France) 
using the Ventana UltraView reagents (for bcl-2, bcl-6, CD10, CD20, CyclinD1 and 
CD3) or on a Bond Immunostainer using the Medite Bond Refine detection system 
(for CD123) (medite Medizintechnik AG, Nunningen, Switzerland). Antigen retrieval 
procedures were applied differentially and appropriate dilutions were chosen for each 
antibody. The sections were counterstained with hematoxylin.30,31 The antibody 
sources, clones and dilutions used in this study are listed in table I. CD123, the α-
chain of interleukine-3-receptor, is expressed mostly on pDC and can therefore be 
used as  immunohistochemical marker for these cells.25,32 First, evaluation was 
performed in a semiquantitative way (none, few, intermediate and high numbers of 
cells). Because this procedure was found to be poorly reproducible, we decided to 
count the cells one by one. In each core pDC were counted using a square ocular 
grid and a blue filter to highlight stained cells at a 200-fold magnification. We counted 
CD123+ plasmacytoid cells that contained discernible nuclei. High endothelial 
venules (HEV), which are equally distinct CD123+, were disregarded. Each entire 
spot was evaluated and we averaged the numbers of corresponding spots for each 
patient. The observer, one and the same for all patients, was blinded to the clinical 
data of the patients. Resulting densities ranged from 0 to 678 cells/mm2.
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Semiquantitative analysis of CD3+ T cells showed a similar poor reproducibility  as 
mentioned above for CD123. In contrast, staining for CD3 was found to be limited to 
T cells and to be strong and homogeneous. It was therefore elected to perform an 
automated quantification. The slide was first scanned spot by spot using a ECLIPSE 
80i Microscope (Nikon, Tokio, Japan) at a tenfold objective magnification linked to a 
video camera (QICAM Fast 1394, Qimaging, Surrey, Canada) and a computer 
controlled motorized stage (Märzhäuser, Wetzlar, Germany). Cells were detected 
with a tissue array analysis software (SpotBrowser Version 2.1.1, Alphelys, Plaisir, 
France). Thresholding of stained cell area for image analysis was achieved by means 
of color, saturation and intensity of the brown immunohistochemical reaction product. 
For statistical computations, the ratio of positive stained area divided by total spot 
area was used and the average of corresponding spots was calculated for each 
patient. Thus, all T cells, regardless of their localization relative to the follicles, were 
measured. Area fractions ranged from 2.4 to 68.4%. Each value and corresponding 
core was checked manually for quality of tissue and staining.
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STATISTICS
Statistical analysis was performed using SPSS Version 15.0.1 (SPSS Inc., Chicago, 
USA). For univariate survival analysis the Kaplan-Meier method and log-rank-test 
were applied.33 Multivariate survival analysis and hazard ratio estimation was done 
by Cox regression. The assumption of constant hazard over time was proven by 
means of log minus log plots.34 Cases with lack of data were excluded from the Cox 
models. For all purposes, overall survival (OS) was defined as the period from date 
of biopsy until death of any cause. Furthermore, we used a non-parametric method 
(Spearman rank correlation) to determine correlations. For crosstabulation analysis 
Fisher’s exact test was applied.
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Results
PATIENT CHARACTERISTICS, CLINICAL AND PATHOLOGICAL VARIABLES
139 patients were included in our study and their characteristics are listed in table II. 
Univariate analysis of available clinical and histological variables revealed significant 
survival differences when patients were grouped according to their age, FLIPI risk 
group (low risk group with score 0-1, intermediate risk group with score 2, and high 
risk group with score 3-5), Ann Arbor stage (I and II versus III and IV), the presence 
of B symptoms and LDH level (normal versus above) (table III). There were no 
significant differences found for patient’s sex, the number of lymph node sites 
involved, hemoglobin level and WHO grading (table III). Patients were also divided in 
groups whether or not they were treated with an anthracycline based chemotherapy 
and whether or not the therapy contained the anti-CD20 agent rituximab. However, 
no significant difference in survival was found between these groups (table III).
PLASMACYTOID DENDRITIC CELLS AND T CELLS
Figure 1 illustrates examples of stained cores for CD123 and CD3. The CD123 
stained TMA slide had samples of 132 patients of sufficient quality for analysis. In 
seven cases the tissue dislocated during epitope retrieval or staining procedure. The 
number of CD123+ cells was highly variable. In cores with many CD123+ cells, an 
interfollicular pattern of distribution was clearly visible (figure 1 C). Distribution of 
CD123+ cell numbers showed a positive skew. A sizable number of spots contained 
only 15 – 30 cells/mm2. The minimum was 0, the maximum 412.5 cells/mm2 with an 
outlier of 678 cells/mm2. The median was 75 cells/mm2, the mean 98 cells/mm2. For 
univariate survival analysis, patients were divided into three groups of equal size 
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according to the tertiles of the CD123+ pDC content. Figure 2 A shows the 
corresponding overall survival curves. High numbers of CD123+ pDC were 
associated with long survival, low numbers CD123+ pDC were associated with 
shorter survival (p < 0.001).  Details are given in table IV. The hazard ratio increased 
twofold from one group to the adjacent, resulting in a fourfold increase from the 
highest to the lowest group. A similar effect was seen irrespective of whether patients 
were treated with an anthracycline based chemotherapy and whether or not the 
therapy contained rituximab. Patients with more CD123+ pDC had a better survival, 
independent of the treatment recieved (p = 0.016 to 0.048, log rank test, except for 
the patients that never received any anthracylines, where the difference was not 
statistically significant, due to the small number of patients (data not shown)). The 
number of pDC cells in relation to the WHO grades 1, 2 and 3 is shown in figure 3. 
No significant differences were found (p = 0.578, Fisher’s exact test).
Physiologically, pDC lie within interfollicular areas.32 We were therefore interested to 
see in what way the number of pDC was due to the presence or loss of the 
interfollicular lymphnode compartment during tumor expansion. To this effect we 
chose a TMA section stained for CD3+ T cells (figure 1 D-F). The stained area 
fraction was determined by automated computer assisted image analysis. 126 
samples were evaluated. Tissue of 13 patients was lost during preparation or showed 
inadequate staining. The frequencies show a Gaussian distribution with a minimum 
of 2.4%, maximum of 68.4%, median of 25%, mean of 27.6% and a standard 
deviation of 13.3%. When dividing patients at the median in two groups of 63 
patients, a significant difference in survival was found with a better prognosis for 
those with many T cells (p = 0.039, hazard ratio 0.56, figure 2 B, table IV). The 
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scatter plot in figure 4 shows a trend towards a positive correlation of T cells and 
pDC, as expected. Spearman’s rank correlation evidences a significant (p < 0.001) 
but weak (r = 0.46) linear association with r2 = 0.21 (figure 4). Thus, only 21% of the 
pDC variation is explained by the variation of the T cell numbers or by the extent of 
the interfollicular compartment, respectively. Additionally, in a multivariate Cox 
regression model including the staining for CD123 and CD3, CD123+ pDC were 
shown to be independent as prognostic factors (p=0.005, table IV). Moreover, 
CD123+ pDC numbers are independent of patient’s age and sex, WHO grading, 
FLIPI and its components and the presence of B symptoms (table III). 
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Discussion
The content of pDC showed a strong association with overall survival. High numbers 
of these cells were associated with long overall survival. Furthermore, subdividing 
patients revealed a distinct dose-response relationship. This quantitative association 
suggests that staining for CD123 could serve as a histological tool to estimate 
patient’s survival and to complement the clinical FLIPI. Poor reproducibility is a well-
known weakness of WHO grading of FL.1 In contrast, pDC are simple to count and, 
thus, quantification should be independent of the examiner. 
PDC are typically found within T cell rich interfollicular areas of lymphoid tissue.32 We 
included this compartment in our analysis by means of staining for CD3+ T cells. 
Evaluation equally showed an association with the clinical course, similar to that of  
CD123+ pDC. High CD3+ T cell contents are also associated with longer survival. 
However, differences are less pronounced.  Because a certain correlation of both cell 
types could be expected due to their presence at the same lymph node 
compartment, a test for redundancy of these results appeared mandatory: On the 
one hand, the correlation of pDC and T cell content was shown to be weak. On the 
other hand, in a multivariate Cox regression model, only the pDC content proved to 
be an independent prognostic factor (table IV). Thus, CD123+ pDC do not seem to 
represent a surrogate measure for loss of the interfollicular T cell compartment during 
tumor progression. Rather, pDC appear to have prognostic impact beyond.
Figure 3 details the relationship of WHO grade and CD123+ cell numbers. The data 
show, that a higher WHO grade is not associated with a decreased number of 
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CD123. An association of WHO grade with CD123+ cell numbers can thus not 
explain the association of CD123+ cell numbers with longer survival. 
The results of the multivariate analysis for WHO grade and CD123+ cell numbers 
(Table 3) show a lack of statistical significance for WHO grade in both univariate and 
multivariate analysis.
PDC have been reported in FL, where they have also been associated with T cell 
subsets.17 PDC have also been described in solid tumors like head and neck 
squamous cell carcinoma, lung cancer and melanoma.22,35 However, to our 
knowledge, no direct association with patient’s survival prognosis was previously 
found and their role in tumor biology remains unclear.35
There is evidence that pDC can infiltrate tumor tissue, though their proper antigen-
presenting capacity might be disabled under these conditions and induction of 
tolerance could result instead.35,36,37 Indeed, under tumor conditions, the function of 
pDC’s has been described to be altered even at sites away from the tumor, i.e. within 
lymphatic tissue and in blood.38,39 On the other hand, pDC perform various functions 
in innate as well as in adaptive immune response. They have been shown to be the 
most prominent cells to produce interferon, especially IFN-α, a type-I-Interferon.22,24-
26
Interferons have immunomodulating and antitumor activity.40,41 Remarkably, IFN-α 
was used with success in therapy of FL before the introduction of rituximab.27 Its role 
in current treatment is controversial.40,42 It is tempting to speculate that pDC provide 
IFN-α endogenously, which otherwise would be provided by external sources, and 
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that this endogenous secretion results in longer survival of patients with high pDC 
numbers. 
Upcoming immunomodulatory therapies include this aspect already: The anti-CD20 
monoclonal antibody rituximab, introduced in 1997 for therapy of low-grade 
lymphomas, has been a great success.43 It is administered as a single agent or in 
multiagent chemotherapy like R-CHOP (rituximab with cyclophosphamide, 
doxorubicin, vincristine and prednisone).44 However, most patients with FL relapse at 
some point and new approaches are needed. One focus of study is to combine 
rituximab with immunomodulatory agents to tap its full antitumoral potential. 
Randomized studies that examine rituximab with IFN-α are indeed ongoing.40
However, the exogenous administration of IFN-α may be limited by its inherent 
toxicity.40 Provision of IFN-α in situ through stimulation of pDC could therefore 
represent an alternative mode of application. Thus, our results support the use of toll-
like receptor (TLR) agonists to stimulate pDC, which is already the object of clinical 
trials.22,45-47
So far, a range of publications have shown that distinct immune cell subsets have an 
impact on the course of the disease in patients with follicular lymphoma. Some of 
these cell subsets, including CD123+ pDC presented in this study, have been 
independently associated with outcome. A comprehensive study, addressing all 
known histological, genetic and clinical factors including therapy, would, however, be 
needed to assess the contributive value of each of the factors.
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While further investigations into the mechanisms of interaction of pDC and lymphoma 
are thus necessary, quantification of pDC in FL may serve to predict survival already 
in current patients with FL.
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LIMITATIONS
The examination was performed on a tissue microarray. The technique is widely 
used to study lymphoma by examining the expression profile of neoplastic cells as 
well as of non tumor cells.15-17,48,49 Validation studies of this approach have shown 
excellent results for many biomarkers.29 However, a correlation study of TMA versus 
full tissue sections of FL could ensure the representativity of the cores stained for 
CD123. This is of particular interest as PDC are found mainly in the interfollicular 
areas and the distribution in the tissue is therefore uneven. 
In our study, we did not account for the causes of death. For the majority of patients, 
precise information was not available. Autopsy was performed only for a small 
percentage of patients. On the other hand, the use of death of any cause could avoid 
issues of exact delineation of lymphoma related death vs. non lymphoma related 
death in patients with multiple co-morbidity. Therefore, we decided not to concentrate 
on disease-related causes of death und instead used overall-survival for statistical 
purposes.
Therapy of our study population was adapted to patients’ age, stage and symptoms. 
One third of the patients were treated using anthracyclines in first-line chemotherapy, 
whereas two-thirds received anthracyclines at some point during their whole clinical 
course. Rituxin and radiotherapy were each applied in another third of patients. 
Indeed, follicular lymphoma is a heterogeneous disease in need for patient adapted 
therapy. Reducing patients to an uniformly treated collective would have resulted in 
the exclusion of a majority of patients and in a relevant loss of statistical power. 
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However, our findings are sufficiently striking, easily reproducible and therefore worth 
to be investigated in an independent validation-set of patients.
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Tables
Table I. Antibodies used in the study.
Antigen Antibody-Clone Manufacturer Dilution
Bcl-2 BCL2/100/D5 Ventana1 prediluted
Bcl-6 GI191E/A8 Cell Marque2 1:50
CD3 SP7 NeoMarkers3 1:100
CD10 56C6 Novocastra4 1:10
CD20 L26 Dako5 1:400
CD123 6H6 eBioscience6 1:100
CyclinD1 SP4 Neomarkers3 1:100
1Ventana Medical Systems S.A., Illkirch, France; 2Cell Marque 
Corporation, Rocklin, California, USA; 3Thermo Fisher 
Scientific, Fremont, California, USA; 4Leica Biosystems, 
Newcastle Upon Tyne, UK; 5Dako Denmark A/S, Glostrup, 
Denmark; 6eBioscience Inc., San Diego, California, USA
Table II. Descriptive statistics of study population.
Feature Number of Patients
Included in the study 139
Sex
  male 60 (43%)
  female 79 (57%)
Median Age (and range), years 58 (32 – 89)
Median Survival (95%-CI), months 106.9 (69.7 - 144.1)
Follow-up
  Mean 90.4 months
  Median 54.6 months
Patients at Risk
  12 months 121 (87.1%)
60 months 62 (47.3%)
120 months 20 (14.4%)
Events
  deceased 59 (42.4%)
  censored 80 (57.6%)
CI indicates confidence interval.
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p-Value* HR† 95%-CI† Variable§ pDC¶
Age 0.001 0.001 < 0.001
  At most 60 years 77 (55.4%) 25 (32.5%) 1
  Above 60 years 62 (44.6%) 34 (54.8%) 2.39 1.41 – 4.05
  Total 139 (100%) 59 (42.4%)
Sex ns ns < 0.001
  Male 60 (43.0%) 26 (43.3%) 1
  Female 79 (57.0%) 33 (41.8%) 1.17 0.70 - 1.96
  Total 139 (100%) 59 (42.4%)
FLIPI 0.001 ns 0.004
  Low-risk 43 (48.9%) 11 (25.6%) 1
  Intermediate 23 (26.1%) 11 (47.8%) 2.46 1.03 – 5.85
  High-risk 22 (25.0%) 12 (54.5%) 4.89 2.04 – 11.69
  Total 88 (100%) 34 (38.6%)
Ann-Arbor stage 0.011 ns 0.043
  1 and 2 35 (34.3%) 8 (22.9%) 1
  3 and 4 67 (65.7%) 32 (47.8%) 2.66 1.21 – 5.81
  Total 102 (100%) 40 (39.2%)
Lymphnode sites# ns ns < 0.001
  At most 4 108 (86.4%) 48 (44.4%) 1
  More than 4 17 (13.6%) 8 (47.1%) 2.03 0.94 - 4.37
  Total 125 (100%) 56 (44.8%)
B-Symptoms** < 0.001 < 0.001 < 0.001
  absent 64 (67.4%) 20 (31.3%) 1
  present 31 (32.6%) 20 (64.5%) 3.15 1.66 – 5.99
  Total 95 (100%) 40 (42.1%)
Hemoglobin ns ns < 0.001
  At least 120 g/L 73 (78.5%) 24 (32.9%) 1
  Less than 120 g/L 20 (21.5%) 9 (45.0%) 2.08 0.96 - 4.50
  Total 93 (100%) 33 (35.6%)
LDH†† < 0.001 0.042 < 0.001
  At most 420 U/L 61 (70.1%) 16 (26.2%) 1
  More than 420 U/L 26 (29.9%) 15 (57.7%) 3.37 1.64 – 6.91
  Total 87 (100%) 31 (35.6%)
WHO-Grade ns ns < 0.001
  1 40 (28.8%) 18 (45.0%) 1
  2 64 (46.0%) 27 (42.2%) 1.22 0.69 - 2.23
  3 35 (25.2%) 14 (40.0%) 1.21 0.60 - 2.45
  Total 139 (100%) 59 (42.4%)
Treatment groups
  Anthracylin based ns ns 0.014
    yes 62 (66.7%) 28 (45.1%) 1
    no 31 (33.3%) 7 (22.6%) 0.58 0.25 – 1.33
    total 93 (100%)
Rituxin based ns ns 0.003
    yes 37 (41.6%) 10 (27.0%) 1
    no 52 (58.4%) 22 (42.3%) 1.88 0.86 – 4.10
    total 89 (100%)
HR, hazard ratio; CI, confidence interval; ns, not significant. *Kaplan-Meier method, log-rank-test; †derives from an univariate 
Cox regression model; ‡Cox regression model including the §variable specified within the grey row and the ¶three groups of 
patients according to the pDC content (0 – 75, 76 – 117 and 118 – 678 cells/mm2, respectively); #Number of lymph node sites 
involved; **B-Symptoms:  loss of body weight, fever, night sweat; ††lactate dehydrogenase.
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p-Value* HR† 95%-CI† Variable§ pDC¶
pDC, cells/mm2 < 0.001 --- ---
0 - 75 43 (32.6%) 29 (67.4%) 1
76 - 117 45 (34.1%) 17 (37.8%) 0.47 0.26 – 0.87
118 - 678 44 (33.3%) 10 (22.7%) 0.25 0.12 – 0.52
  Total 132 (100%) 56 (42.4%)
T cells, %‡‡ 0.039 ns 0.005
2.4 - 25 63 (50%) 31 (49.2%) 1
25.1 - 68.4 63 (50%) 21 (33.3%) 0.56 0.32 – 0.98
Total 126 (100%) 53 (42.7%)
HR, hazard ratio; CI, confidence interval; ns, not significant. *Kaplan-Meier method, log-rank-test; †derives from an univariate 
Cox regression model; ‡Cox regression model including the §variable specified within the grey row and the ¶three groups of 
patients according to the pDC content (0 – 75, 76 – 117 and 118 – 678 cells/mm2, respectively); #Number of lymph node sites 
involved; **B-Symptoms:  loss of body weight, fever, night sweat; ††lactate dehydrogenase; ‡‡stained area fraction.
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Figure Legends
Figure 1. Representative 0.65 mm TMA spots stained for CD123+ pDC (A - C) 
and for CD3+ T cells (D - E). ECLIPSE 80i Microscope (Nikon, Tokio, Japan), 
original magnification x10. Captured with a video camera (QICAM Fast 1394, 
Qimaging, Surrey, Canada). In picture A – C, an blue filter is used for better 
visualization of stained pDC. With increasing densities of pDC an interfollicular 
distribution of pDC is emerging (C). The microphotographs of staining for CD3 show 
the range of interfollicular T cell density. Images for CD123 and CD3 do not 
represent corresponding TMA cores.
Figure 2 A. Kaplan-Meier survival curves for CD123+ pDC numbers/mm2 . 
Patients were divided into three equal groups. Group 2 consists of one more patient, 
because there were two patients with exactly the same cell number at the 
intersection between group 1 and 2. Higher CD123 cell number associate with longer 
survival (p < 0.001, log rank test). B. Kaplan-Meier survival curves for stained 
CD3+ T cell area fractions. The quantification was performed by automated 
computer assisted image analysis. Results are expressed as fraction of stained area 
divided by total spot area. Group 2 (upper half of patients) with 25.1 – 68.4% of 
stained spot area shows a longer time of survival than group 1 (lower half of patients) 
with fewer cells (p = 0.039, log rank test).
Figure 3. Bar plot that shows the pDC cell numbers in relation to the WHO 
grading. No significant differences were found considering the crosstabulation (p = 
0.578, fisher’s exact test). ns, not significant.
Figure 4. Scatter plot of CD3+ T cells and CD123+ pDC. X axis: CD3+ stained 
area fraction, Y axis: CD123+ cells/mm2. Spearman’s rank correlation. The conjoint 
interfollicular localisation of pDC and T cells results in a significant positive 
correlation (r = 0.46, p < 0.001). However, only 21% of the pDC variation is due to 
the variation of the T cell numbers or of the extension of the interfollicular 
compartment, respectively (r2 = 0.21).
